Related Articles
Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone
Interim 18F‑FDG PET/CT improves the prognostic value of S‑IPI, R‑IPI and NCCN‑IPI in patients with diffuse large B‑cell lymphoma
A modified prognostic model in patients with diffuse large B‑cell lymphoma treated with immunochemotherapy
miR‑150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B‑cell lymphoma
Central nervous system involvement in adult patients with diffuse large B-cell lymphoma: Influence of rituximab